<DOC>
	<DOC>NCT00224068</DOC>
	<brief_summary>This study evaluates the safety and efficacy of FerrlecitÂ® (ferric gluconate; a form of intravenous iron) or ferrous sulfate (a form of oral iron) in improving the response to epoetin alfa among anemic cancer patients receiving chemotherapy.</brief_summary>
	<brief_title>Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric gluconate</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Diagnosis of nonmyeloid malignancy Moderate to severe anemia Adequate iron stores as measured by either TSAT or ferritin About to start cycle of chemotherapy Eligible for epoetin alfa therapy Highly elevated TSAT or ferritin Recent transfusion, epoetin alfa, darbepoetin or intravenous iron Medical conditions that would confound the efficacy evaluation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Iron deficiency</keyword>
	<keyword>Sodium ferric gluconate</keyword>
	<keyword>anemia</keyword>
	<keyword>cancer chemotherapy</keyword>
	<keyword>epoetin alfa</keyword>
	<keyword>Anemia/drug therapy</keyword>
	<keyword>Anemia, Iron-Deficiency/drug therapy/etiology</keyword>
	<keyword>Hematinics/administration &amp; dosage/pharmacology</keyword>
	<keyword>Antineoplastic Agents/adverse effects</keyword>
	<keyword>Erythropoietin, Recombinant/therapeutic use/adverse effects</keyword>
</DOC>